Three-year purchase agreement negotiated with McNicoll, Lewis & Vlak
By Devika Patel
Knoxville, Tenn., June 30 - Aeterna Zentaris Inc. said it negotiated an at-the-market sales agreement with McNicoll, Lewis & Vlak LLC as agent on June 29. The investor is also the agent
The company may sell up to 9.5 million common shares over two years on the Nasdaq. The purchase price of the shares will vary.
Aeterna Zentaris is a biopharmaceutical company focused on endocrine therapy and oncology based in Quebec City, Quebec.
| Issuer: | Aeterna Zentaris Inc.
|
| Issue: | At-the-market sales agreement
|
| Amount: | 9.5 million shares
|
| Tenor: | Two years
|
| Warrants: | No
|
| Agent: | McNicoll, Lewis & Vlak LLC
|
| Pricing date: | June 29
|
| Stock symbol: | Nasdaq: AEZS
|
| Stock price: | $2.21 at close June 29
|
| Market capitalization: | $203.7 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
